FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
the finding matters only as far as its evidence, limitations and independent verification can carry it.
By Nivegu News Desk
What happened
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis.
Why it matters
the finding matters only as far as its evidence, limitations and independent verification can carry it.
What happens next
peer review, replication and disclosed uncertainty.